- News Home
6 March 2014 1:04 pm ,
Vol. 343 ,
Considered an icon of conservation science, researchers at World Wildlife Fund (WWF) headquarters in Washington, D.C.,...
The new atlas, which shows the distribution of important trace metals and other substances, is the first product of...
Early in April, the first of a fleet of environmental monitoring satellites will lift off from Europe's spaceport in...
Since 2000, U.S. government health research agencies have spent almost $1 billion on an effort to churn out thousands...
Magdalena Koziol, a former postdoc at Yale University, was the victim of scientific sabotage. Now, she is suing the...
Antiretroviral drugs can protect people from becoming infected by HIV. But so-called pre-exposure prophylaxis, or PrEP...
Two studies show that eating a diet low in protein and high in carbohydrates is linked to a longer, healthier life, and...
- 6 March 2014 1:04 pm , Vol. 343 , #6175
- About Us
Heart Leader Signs Off
8 July 2003 (All day)
The longest-serving director of the National Heart, Lung, and Blood Institute (NHLBI) announced last week that he will step down. Claude Lenfant plans to retire on 30 August, after 21 years as NHLBI's director.
Lenfant, a former heart surgeon, previously served as director of the Fogarty International Center (1981-1982) and director of the NHLBI lung division (1970-1981). In all, he has worked with seven directors of the National Institutes of Health (NIH). Elias Zerhouni, the current head, issued a statement praising Lenfant as a "talented and capable administrator" and "first-class scientist" whose departure will leave "a significant loss."
Among NIH senior staff, Lenfant is known as an experienced manager who takes pride in keeping his $2.8 billion agency on an even keel. "Claude knows his institute inside and out; he has been an excellent spokesperson for his research community," says Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases.
Lenfant, 74, was on leave and could not be reached for comment. But in an earlier interview, he said "one of my best investments" was $15 million spent on training ambulance crews to treat heart attack patients more rapidly. He also was proud that the NHLBI had been first to pursue gene therapy treatments, although their initial promise hasn't panned out.
Last year, Lenfant championed a controversial study involving patients with serious respiratory problems. On 3 July, the same week that Lenfant announced his retirement, the Office for Human Research Protections (OHRP), which monitors the use of subjects in experimental trials, released a year-long hold it had placed on the study, which involves 19 institutions and is funded by NHLBI. OHRP had been reviewing the ethical implications of the $37 million clinical trial, a test of ventilator treatments (Science, 23 May 2003, p. 1225). After OHRP's decision, investigators said they intended to resume the trial in a few months.